Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors

Haemophilia

Volumn 15, Issue 5, 2009, Pages 1065-1073

  Kenet, G ^a,c   Lubetsky, A ^a   Luboshitz, J ^a   Ravid, B ^a   Tamarin, I ^a   Varon, D ^b   Martinowitz, U ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

FXI deficiency; Inhibitors; RFVIIa; Thromboelastography

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CREATINE KINASE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ACALCULOUS CHOLECYSTITIS; ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; BACTERIAL ENDOCARDITIS; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD SAMPLING; BOLUS INJECTION; CASE REPORT; COLON RESECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART EJECTION FRACTION; HEART INFARCTION; HEMOSTASIS; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; LAPAROTOMY; LOW DRUG DOSE; MALE; NEPHRECTOMY; PERITONITIS; PLEURA EFFUSION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOPHLEBITIS; THROMBOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VITRECTOMY;

BLOOD COAGULATION FACTOR INHIBITORS; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; FACTOR XI DEFICIENCY; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS;

EID: 69949102958     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02043.x     Document Type: Article

References (52)

1. He R, Xiong S, He X et al. The role of factor XI in a dilute thromboplastin assay of extrinsic coagulation pathway. Thromb Haemost 2001; 85: 1055-9.
2. Minnema MC, Ten Cate H, Hack CE. The role of factor XI in coagulation: A matter of revision. Semin Thromb Hemost 1999; 25: 419-28.
3. Brummel KE, Paradis S, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
4. Bouma BM, Meijers JC. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol 2000; 7: 266-72.
5. Bolton-Maggs PH. Factor XI deficiency. Baillieres Clin Haematol 1996; 9: 355-68.
6. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Eng J Med 1991; 325: 153-8.
7. Vercelloti GM, Mosher DF. Acquired factor XI deficiency in systemic lupus erythematosus. Thromb Haemost 1982; 48: 250-2.
8. Chediak J, Madej-Zevin P, Ratnoff OD, Goldsmith GH, Everson B. Studies on a circulating anticoagulant inhibiting factor XI in a patient with congenital factor XI deficiency and carcinoma of the prostate. Br J Haematol 1986; 63: 123-33.
9. Goodrick MJ, Prentice AG, Copplestone JA, Pamphilon DH, Boon RJ. Acquired factor XI inhibitor in chronic lymphocytic leukemia. J Clin Pathol 1992; 45: 352-3.
10. Billon S, Blouch MT, Escoffre-Barbe M, Le Niger C, Le Roux AM, Abgrall JF. A case of chronic myelomonocytic leukemia and factor XI deficiency with a circulating anticoagulant. Hemophilia 2001; 7: 433-6.
11. Stern D, Nosell HL, Owen J. Acquired antibody to factor XI in a patient with congenital factor XI deficiency. J Clin Invest 1982; 69: 1270-6.
12. Reece EA, Clyne LP, Romero R, Hobbins JC. Spontaneous factor XI inhibitors. Seven additional cases and a review of the literature. Arch Intern Med 1984; 144: 525-9.
13. Morgan K, Schiffman S, Feinstein D. Acquired factor XI inhibitors in two patients with hereditary factor XI deficiency. Thromb Haemost 1984; 51: 371-5.
14. Musclow CE, Amato D, Ofosu F, Armstrong AL, Abbot D. Transfusion-induced specific anti factor XI inhibitor in a patient with previously unrecognized factor XI deficiency. Am J Clin Pathol 1988; 89: 418-22.
15. Schnall SF, Clyne LP. Acquired factor XI inhibitors in congenitally deficient patients. Am J Hematol 1987; 26: 323-8.
16. Salomon O, Zivelin A, Livnat T et al. Prevalence, causes and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101: 4783-8.
17. Rolvic Z, Elezovic I, Obrenovic B, Rizza C. Life threatening bleeding due to an acquired inhibitor to factor XII-XI successfully treated with activated prothrombin complex concentrate (Feiba). Br J Haematol 1982; 51: 659-65.
18. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100: 557-62.
19. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of high dose factor VIIa independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9: S15-20.
20. Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Hemostasis 1996; 26: 159-64.
21. Poon MC, Demers C, Wu JWY et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann Thrombasthenia. Blood 1999; 94: 3951-3.
22. Bernstein DE, Jeffers L, Erhardsen E et al. Recombinant activated factor VIIa corrects prothrombin time in cirrhotic patients - a preliminary study. Gastroenterology 1997; 113: 1930-7.
23. Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-8.
24. Billon S, Le Niger C, Escoffre-Barbe M, Vicariot M, Abgrall JF. The use of recombinant factor VII (Novoseven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 551-3.
25. Lawler P, White B, Pye S et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to FXI deficiency. Haemophilia 2002; 8: 145-8.
26. Bern MM, Sahud M, Zhukov O, Qu K, Mitchell W Jr. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 2005; 11: 20-5.
27. Brown SA. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia 2005; 11: 430-1.
28. Schulman S, Nemeth G. An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Hemophilia 2006; 12: 223-7.
29. Avci Z, Malbora B, Gokdemir M, Ozkan S, Ozbek N. Successful use of recombinant factor VIIa (Novoseven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency. Pediatr Cardiol 2008; 29: 220-2.
30. O'Conell NM, Riddell AF, Pascoe G, Perry DJ, Lee CA. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia 2008; 14: 775-81.
31. Schulman S, d'Oiron R, Martinowitz U et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S97-101.
32. Batorova A, Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006; 13: 308-15.
33. Sørensen B, Ingerslev J. Whole blood clot formation phenotypes on haemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
34. Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16: 37-41.
35. Salomon O, Steinberg DM, Seligsohn U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12: 490-3.
36. Ginsberg SS, Clyne LP, McPherdran P, Duffy TP, Hanson T. Successful childbirth by a patient with congenital factor XI deficiency and an acquired inhibitor. Br J Haematol 1993; 84: 172-4.
37. Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost 2006; 4: 192-200.
38. Monroe DM. Further understanding of recombinant activated factor VII mode of action. Semin Hematol 2008; 2 (Suppl. 1): S7-11.
39. Hultin MB. Fibrinogen and factor VII as risk factors in vascular disease. Prog Haemost Thromb 1991; 10: 215-41.
40. Merlini PA, Ardissino D, Oltrona L, Broccolino M, Coppola R, Mannuci PM. Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arteriscler Thromb Vasc Biol 1995; 15: 1675.
41. Wang X, Cheng Q, Xu L et al. Effects of factor IX or factor XI deficiency on ferric chloride induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
42. Wang X, Smith PL, Hsu MY, Gailani D, Ogletree ML, Seiffert DA. Effects of factor XI deficiency on ferric chloride induced vena cava thrombosis in mice. J Thromb Haemost 2006; 4: 1982-8.
43. Salomon O, Steinberg DM, Dardik R et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost. 2003; 1: 658-61.
44. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-7.
45. Peerlink K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novoseven) in a patient with hemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
46. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
47. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia. 2008; Aug 4. 14 (5): 898-902.
48. Young G, Ebessen LS, Viuff D et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: A multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
49. Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia 2008; 14 (Suppl. 4): 20-7.
50. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14 (Suppl. 3): 83-92.
51. Dirkman D, Hanke AA, Gorlinger K, Peters J. Perioperative use of modified thromboelastography in factor XI deficiency: A helpful method to assess drug effects. Acta Anaesthesiol Scand 2007; 51: 640-3.
52. Wolberg AS, Aleen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-55.